The role of biomarker in later-line treatment for metastatic colorectal cancer

[摘要] Trifluridine/tipiracil (FTD/TPI) is an oral drug that inhibits thymidylate synthase, interfering with DNA synthesis (1). FTD/TPI monotherapy demonstrated efficacy for overall survival in heavily treated metastatic colorectal cancer (mCRC) in the RECOURSE trial with a hazard ratio (HR) of 0.68 [95% confidence interval (CI): 0.58–0.81] against the placebo (1). FTD/TPI is widely used as the standard later-line treatment worldwide (2-4), and its efficacy and safety have been reproduced in real-world data (RWD) (5,6). Regorafenib is also a late-line treatment option, and it remains an important clinical question whether FTD/TPI or regorafenib should be administered first. As administration of all active drugs has been shown to improve survival of mCRC (7,8), information on predictive biomarkers is helpful for patient selection and for improving prognosis.

[学科分类] 肿瘤学

[关键词] Metastatic colorectal cancer;later-line treatment;biomarker